Search
Hypertension Paid Clinical Trials in South Carolina
A listing of 17 Hypertension clinical trials in South Carolina actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 17
The state of South Carolina currently has 17 active clinical trials seeking participants for Hypertension research studies. These trials are conducted in various cities, including Charleston, Greenville, Spartanburg and Columbia.
Featured Trial
Cardiovascular Disease Trials
Recruiting
Cardiovascular Disease trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Cardiovascular Disease
Featured Trial
55+ Obesity and Cardiovascular Disease Clinical Study
Recruiting
Diagnosed with cardiovascular disease? Join our local overweight with cardiovascular issues clinical trial. Every 34 seconds, someone in the US dies of cardiovascular disease. Wonder how you could help? If you’re eligible for our CVD clinical trial, you could receive up to $1500.
Conditions:
Obesity
Overweight and Obesity
Cardiovascular Disease
Cardiovascular Diseases
Cardiovascular Health
Featured Trial
Cardiovascular Disease and Obesity Study
Recruiting
Overweight individuals diagnosed with type 2 diabetes
Featured Trial
Chronic Kidney Disease and High Blood Pressure
Recruiting
Conditions:
Kidney Disease
Chronic Kidney Disease
* Compensation for time may be available
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Healthy Volunteer Trials
Recruiting
Healthy trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Healthy
A Long-term Follow-up Study of Sotatercept for PAH Treatment (MK-7962-004/A011-12)
Recruiting
This study is being conducted to assess the long-term safety, tolerability, and efficacy of sotatercept (MK-7962, formerly called ACE-011) in participants with Pulmonary Arterial Hypertension (PAH). This open-label, long-term follow-up (LTFU) study is supported by data from the PULSAR study (Phase 2, NCT03496207) in which treatment with sotatercept resulted in hemodynamic and functional improvements in the study participants, including those receiving maximal PAH therapy with double/triple drug... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: Medical University of South Carolina - PPDS ( Site 1003), Mount Pleasant, South Carolina
Conditions: PAH, Pulmonary Arterial Hypertension
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
Recruiting
The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary arterial hypertension (PAH) compared to macitentan 10 mg.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: AnMed Health, Anderson, South Carolina
Conditions: Pulmonary Arterial Hypertension
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
Recruiting
This study will evaluate the efficacy of TNX-103 (levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
06/14/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Pulmonary Hypertension
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)
Recruiting
This is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of sotatercept versus placebo in adults with Cpc-PH due to HFpEF.
The objective of this study is to evaluate the efficacy, safety and tolerability of sotatercept versus placebo in adults with Cpc-PH due to HFpEF. Efficacy is measured by change from baseline in pulmonary vascular resistance (PVR, primary endpoint) and 6-minute walk distance (6MWD, key secondary endpoint).
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
06/14/2024
Locations: Medical University of South Carolina - PPDS ( Site 1003), Charleston, South Carolina
Conditions: Hypertension, Pulmonary
A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).
Recruiting
Study KER-012-A201 is Phase 2, double-blind, randomized, placebo-controlled study to determine the efficacy and safety of KER-012 compared to Placebo in adults with PAH (WHO Group 1 PH) on stable background PAH therapy. The study is divided into the Screening Period, Treatment Period, Extension Period, and Follow-Up Period.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/12/2024
Locations: TROPOS Study Site 106, Charleston, South Carolina
Conditions: Pulmonary Arterial Hypertension
A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen
Recruiting
a Phase 2 trial to evaluate the blood pressure-lowering effect of lorundrostat (an aldosterone synthase inhibitor), administered on a background of a standardized anti-hypertensive (AHT) medication regimen, in subjects with uncontrolled and/or treatment-resistant hypertension.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: Accelerated Enrollment Solutions (AES)- Anderson, Anderson, South Carolina +2 locations
Conditions: Hypertension
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
Recruiting
The primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III. The secondary objective for this trial is to determine time to clinical worsening.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/10/2024
Locations: Medical University of South Carolina - Nexus Research Center, Charleston, South Carolina
Conditions: Pulmonary Arterial Hypertension
Open-Label Extension Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Uncontrolled Hypertension
Recruiting
This study is to evaluate the long-term safety, efficacy and tolerability of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled hypertension.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Coastal Carolina Research Center, North Charleston, South Carolina
Conditions: Hypertension
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
Recruiting
The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation.
Additionally, long-term follow-up data will also be collected from eligible subjects previously treated in the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED studies.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/07/2024
Locations: AnMed Health Medical Center, Anderson, South Carolina
Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)
Recruiting
The objective of this study is to evaluate the effects of sotatercept (MK-7962, formerly called ACE-011) treatment (plus background pulmonary arterial hypertension (PAH) therapy) versus placebo (plus background PAH therapy) on time to clinical worsening (TTCW) in participants who are newly diagnosed with PAH and are at intermediate or high risk of disease progression.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/30/2024
Locations: Medical University of South Carolina ( Site 1003), Charleston, South Carolina
Conditions: Pulmonary Arterial Hypertension
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
Recruiting
The purpose of this study is to measure the efficacy and safety of baxdrostat/dapagliflozin in participants ≥ 18 years of age with CKD and HTN. This study consists of a screening, a 4-week dapagliflozin run-in period for participants naïve to SGLT2i at baseline; a 24-month double-blind period in which participants will receive either baxdrostat/dapagliflozin or dapagliflozin; and a 6-week open-label period in which all participants will discontinue baxdrostat/placebo and receive dapagliflozin al... Read More
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
05/22/2024
Locations: Research Site, Columbia, South Carolina
Conditions: Chronic Kidney Disease and Hypertension
A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2
Recruiting
This study is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
05/21/2024
Locations: Research Site, Rock Hill, South Carolina
Conditions: Pulmonary Hypertension (World Health Organization Group 2), Heart Failure
1 - 12 of 17